Pfizer Total Liabilities 2010-2025 | PFE
Pfizer total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Pfizer total liabilities for the quarter ending June 30, 2025 were $117.083B, a 8.68% decline year-over-year.
- Pfizer total liabilities for 2024 were $124.899B, a 8.97% decline from 2023.
- Pfizer total liabilities for 2023 were $137.213B, a 35.47% increase from 2022.
- Pfizer total liabilities for 2022 were $101.288B, a 2.62% decline from 2021.
Pfizer Annual Total Liabilities
(Millions of US $) |
| 2024 |
$124,899 |
| 2023 |
$137,213 |
| 2022 |
$101,288 |
| 2021 |
$104,013 |
| 2020 |
$90,756 |
| 2019 |
$104,148 |
| 2018 |
$95,664 |
| 2017 |
$100,141 |
| 2016 |
$111,776 |
| 2015 |
$102,384 |
| 2014 |
$95,944 |
| 2013 |
$95,481 |
| 2012 |
$104,120 |
| 2011 |
$105,381 |
| 2010 |
$106,749 |
| 2009 |
$122,503 |
Pfizer Quarterly Total Liabilities
(Millions of US $) |
| 2025-06-30 |
$117,083 |
| 2025-03-31 |
$117,391 |
| 2024-12-31 |
$124,899 |
| 2024-09-30 |
$126,918 |
| 2024-06-30 |
$128,218 |
| 2024-03-31 |
$128,537 |
| 2023-12-31 |
$137,213 |
| 2023-09-30 |
$117,817 |
| 2023-06-30 |
$120,875 |
| 2023-03-31 |
$94,381 |
| 2022-12-31 |
$101,288 |
| 2022-09-30 |
$102,459 |
| 2022-06-30 |
$107,821 |
| 2022-03-31 |
$101,155 |
| 2021-12-31 |
$104,013 |
| 2021-09-30 |
$103,221 |
| 2021-06-30 |
$99,605 |
| 2021-03-31 |
$89,953 |
| 2020-12-31 |
$90,756 |
| 2020-09-30 |
$113,487 |
| 2020-06-30 |
$113,370 |
| 2020-03-31 |
$100,998 |
| 2019-12-31 |
$104,148 |
| 2019-09-30 |
$105,051 |
| 2019-06-30 |
$96,274 |
| 2019-03-31 |
$96,263 |
| 2018-12-31 |
$95,664 |
| 2018-09-30 |
$96,174 |
| 2018-06-30 |
$94,856 |
| 2018-03-31 |
$94,071 |
| 2017-12-31 |
$100,141 |
| 2017-09-30 |
$111,041 |
| 2017-06-30 |
$109,863 |
| 2017-03-31 |
$110,038 |
| 2016-12-31 |
$111,776 |
| 2016-09-30 |
$114,829 |
| 2016-06-30 |
$107,592 |
| 2016-03-31 |
$99,582 |
| 2015-12-31 |
$102,384 |
| 2015-09-30 |
$103,743 |
| 2015-06-30 |
$93,698 |
| 2015-03-31 |
$93,053 |
| 2014-12-31 |
$95,944 |
| 2014-09-30 |
$93,057 |
| 2014-06-30 |
$95,656 |
| 2014-03-31 |
$93,740 |
| 2013-12-31 |
$95,481 |
| 2013-09-30 |
$97,167 |
| 2013-06-30 |
$100,358 |
| 2013-03-31 |
$104,571 |
| 2012-12-31 |
$104,120 |
| 2012-09-30 |
$100,488 |
| 2012-06-30 |
$102,881 |
| 2012-03-31 |
$102,006 |
| 2011-12-31 |
$105,381 |
| 2011-09-30 |
$105,602 |
| 2011-06-30 |
$106,936 |
| 2011-03-31 |
$104,423 |
| 2010-12-31 |
$106,749 |
| 2010-09-30 |
$103,347 |
| 2010-06-30 |
$104,193 |
| 2010-03-31 |
$105,031 |
| 2009-12-31 |
$122,503 |
| 2009-09-30 |
$75,044 |
| 2009-06-30 |
$76,104 |
| 2009-03-31 |
$62,491 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
